Animol Discovery utilizes machine learning and DNA-encoded chemical libraries to develop targeted pharmaceuticals for veterinary patients. The startup addresses the lack of effective treatment options in veterinary medicine by accelerating the discovery of safer and more effective small molecules tailored to animal health needs.
Funding
$44M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Veterinary medicine lacks effective and safe treatment options for many animal diseases, hindering the standard of care for both companion and farm animals. Traditional drug discovery methods are often slow and inefficient, delaying the availability of novel pharmaceuticals tailored to the specific needs of veterinary patients.
Solution
Animol Discovery is developing targeted pharmaceuticals for animals by integrating machine learning with DNA-encoded chemical libraries. The company's approach combines genomics analysis, billions of molecules from DNA-encoded libraries, artificial intelligence, and computational chemistry to accelerate the identification of innovative medicines. This technology enables the discovery of more effective and safer small molecules, addressing unmet needs in animal health without compromising safety or efficacy. The company aims to improve the standard of care for animals by providing novel treatments substantially faster than traditional methods.
Target Audience
The primary target audience includes veterinarians and animal health professionals seeking advanced pharmaceutical solutions for companion and farm animals.
Features
- Utilizes DNA-encoded chemical libraries to screen billions of molecules.
- Employs machine learning and artificial intelligence to identify promising drug candidates.
- Integrates genomics analysis and computational chemistry for targeted drug design.
- Focuses on developing small molecule pharmaceuticals tailored to veterinary patients.
- Aims to accelerate the drug discovery process for animal health applications.